预约演示
更新于：2026-03-27
Cisplatin
顺铂
更新于：2026-03-27
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式Cl2H6N2Pt |
InChIKeyWCLAIRSNZFYZAT-UHFFFAOYSA-N |
CAS号15663-27-1 |
关联
4,364
项与 顺铂 相关的临床试验NCT04910386
A Randomized, Open-Label, Multicenter Phase 2 Study of Envafolimab in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin as the First-line Treatment in Patients With Locally Advanced or Metastatic Biliary Tract Cancers
NCT04595981
Chemo-embolization for Head and Neck Cancer
NCT07281417
Neoadjuvant Chemotherapy With or Without Cemiplimab (REGN2810) in Sinonasal Squamous Cell Carcinoma: A Randomized Phase 2 Study
100 项与 顺铂 相关的临床结果
登录后查看更多信息
100 项与 顺铂 相关的转化医学
登录后查看更多信息
100 项与 顺铂 相关的专利（医药）
登录后查看更多信息
92,285
项与 顺铂 相关的文献（医药）2026-12-31CANCER BIOLOGY & THERAPY
Identification of coilin in bone marrow as a potential neuroblastoma tumor progression marker transcriptionally regulated by MYCN
Article
作者: Zhao, Wen ; Gao, Chao ; Cui, Chunying ; Su, Yan ; Xue, Tianlin ; Duan, Chao ; Li, Lan ; He, Sidou ; Liu, Shuguang ; Yue, Zhixia
BACKGROUND:
Current risk stratification for neuroblastoma (NB) relies on limited markers like MYCN amplification. Coilin, a key Cajal body component, regulates cellular processes. This study investigates whether coilin expression in bone marrow (BM) serves as a predictive biomarker for NB progression and elucidate its function in this disease.
METHODS:
The functions and molecular mechanisms of coilin were investigated by employing cell lines and animal models. Coilin mRNA levels in patient samples were measured by RT-PCR, and their relationships with clinicobiological characteristics and outcomes were analyzed.
RESULTS:
Cisplatin induced dramatic changes of coilin distribution and expression. Databases showed that high expression of coilin exerted predictive values for poor outcome in NB. Coilin promoted proliferation in vitro and in vivo. Knockdown of coilin expression inhibited cell migration and invasion, promoted apoptosis and increased the Cisplatin drug sensitivity. Moreover, coilin activates p53/p21 signaling pathway and was a direct target of MYCN. Analysis of BM samples demonstrated that high expression of coilin was obviously associated with adverse clinical biological features. Importantly, the levels of coilin at diagnosis were markedly higher than those at the time before maintenance treatment in the exact paired patients. Survival analysis presented that high coilin expression in BM is associated with poor prognosis.
CONCLUSIONS:
A novel and accessible coilin-targeted liquid biopsy method was developed, capable of detecting minimal residual disease (MRD) in early-stage NB and predicting disease progression and recurrence. Coilin was transcriptionally regulated by MYCN, offering potential avenues for the development of novel drugs or intervention strategies.
2026-12-31OncoImmunology
Multidimensional immune profiling uncovers biphasic peripheral T-cell dynamics after chemoradiation in patients with locally advanced head and neck cancer
Article
作者: Arnier, Rudy ; Ndao, Babacar ; Mirjolet, Céline ; Adotevi, Olivier ; Thibouw, David ; Guo, Junming ; Boustani, Jihane ; Lecoester, Benoît ; Renaudin, Adeline ; Xie, Yaoyao ; Vulquin, Noémie ; Sun, Xushan ; Vernerey, Dewi ; Pernot, Mandy ; Meurisse, Aurelia ; Boisson, Cyril ; Chevalier, Cédric ; Malfroy, Marine ; Laheurte, Caroline ; Benhmida, Salim ; Boullerot, Laura
Cisplatin-based concurrent chemoradiation (CRT) remains the standard treatment for locally advanced head and neck squamous cell carcinoma (LA-HNSCC), yet recurrence rates remain high. Attempts to combine immune checkpoint inhibitors with CRT have not improved outcomes, underscoring the need to better understand CRT-driven immunologic dynamics. Here, we performed longitudinal, multidimensional profiling of peripheral immunity in patients with LA-HNSCC at baseline (BSL), one month (CRT-1M), and three months (CRT-3M) after platinum-based CRT. CRT induced a transient reduction in tumor-reactive Th1 responses at CRT-1M, followed by marked expansion by CRT-3M. Consistently, genes involved in T-cell activation, polarization, and exhaustion exhibited a biphasic pattern with delayed upregulation at CRT-3M. Transcriptomic analyses of blood lymphocytes revealed an early shift from B-cell- to T-cell-mediated pathways over time during CRT. Integrated analyses including immunosuppressive cells and soluble mediators showed that the early decline in tumor-reactive T cells coincided with increased immunosuppressive cells, T-cell exhaustion, and elevated protumoral cytokines such as IL-8, IL-1β, and IL-10. In contrast, robust expansion of tumor-reactive T cells dominated the peripheral immune landscape at CRT-3M. Together, these data reveal the dynamic remodeling of peripheral immunity following platinum-based CRT and identify a delayed peripheral immune activation phase that may represent an optimal window for combining CRT with immune checkpoint blockade.
2026-12-31Hematology
XPO1 Inhibition enhances sensitivity to platinum-based chemotherapy in germinal-center B-cell-like-DLBCL cells
Article
作者: Wei, Yongqiang ; Wei, Xiaolei ; Feng, Ru ; Su, Qiongqiong
PURPOSE:
Platinum-based chemotherapy is considered as salvage therapy to relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients. However, treatment failure due to drug resistance occurs in some patients, particularly those with Exportin 1 (XPO1) overexpression. This study investigates whether XPO1 inhibition enhances platinum sensitivity in DLBCL subtypes.
METHODS:
XPO1 expression in DLBCL was predicted using online datasets. Cell lines representing DLBCL subtypes were treated with varying concentrations of the XPO1 inhibitor selinexor (XPO1i), cisplatin (CDDP), and oxaliplatin (OXA), alone or in combination. Cellular viability was assessed via CCK-8 assay, while apoptosis rates and reactive oxygen species (ROS) levels were measured by flow cytometry. Protein levels of XPO1 and pro-apoptotic cytokines were evaluated using Western blotting.
RESULTS:
Bioinformatic analysis revealed elevated XPO1 expression in DLBCL. Both XPO1i and platinum-based therapy inhibited cellular viability and promoted apoptosis across DLBCL subtypes in a dose-dependent fashion. The combination of XPO1i at its IC50 and CDDP synergistically suppressed cell viability across both activated B-cell-like- and germinal-center B-cell-like (GCB)-DLBCL subtypes compared to CDDP monotherapy. The combination of XPO1i at its IC30 and OXA synergistically led to a greater reduction in cell viability, along with enhanced induction of apoptosis and ROS accumulation in GCB-DLBCL cells. In OCI-Ly8 and OCI-Ly1 cells, OXA alone inhibited phosphorylation of AKT and mTOR while increasing phosphorylation of JNK, ATM, and p53, and expression of γH2AX; these effects were potentiated by the combination of XPO1i and OXA.
CONCLUSION:
XPO1 inhibition enhances platinum-induced cytotoxicity in GCB-DLBCL, supporting clinical evaluation of XPO1i-platinum combinations as salvage therapy.
4,404
项与 顺铂 相关的新闻（医药）100 项与 顺铂 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 胆道癌 | 日本 | 2012-02-22 | |
| 头颈部鳞状细胞癌 | 巴西 | 2007-01-22 | |
| 恶性胸膜间皮瘤 | 日本 | 2007-01-04 | |
| 儿童恶性实体瘤 | 日本 | 2005-09-15 | |
| 淋巴瘤 | 日本 | 2005-09-15 | |
| 骨癌 | 日本 | 2005-02-14 | |
| 子宫内膜癌 | 日本 | 2005-02-14 | |
| 生殖细胞瘤 | 日本 | 2004-05-31 | |
| 肝细胞癌 | 日本 | 2004-01-29 | |
| 骨肉瘤 | 日本 | 1999-12-21 | |
| 小细胞肺癌 | 日本 | 1999-12-21 | |
| 实体瘤 | 中国 | 1995-01-01 | |
| 实体瘤 | 中国 | 1995-01-01 | |
| 实体瘤 | 中国 | 1995-01-01 | |
| 实体瘤 | 中国 | 1995-01-01 | |
| 实体瘤 | 中国 | 1995-01-01 | |
| 胃癌 | 日本 | 1990-06-03 | |
| 食管癌 | 日本 | 1988-05-30 | |
| 神经母细胞瘤 | 日本 | 1988-05-30 | |
| 宫颈癌 | 日本 | 1988-05-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 口腔鳞状细胞癌 | 临床3期 | 美国 | 2024-11-07 | |
| 输卵管癌 | 临床3期 | 美国 | 2024-03-08 | |
| 原发性腹膜癌 | 临床3期 | 美国 | 2024-03-08 | |
| 肺癌 | 临床3期 | 美国 | 2023-02-01 | |
| 肺癌 | 临床3期 | 美国 | 2023-02-01 | |
| 转移性宫颈癌 | 临床3期 | 中国 | 2022-09-23 | |
| 复发性宫颈癌 | 临床3期 | 中国 | 2022-09-23 | |
| 肝内胆管癌 | 临床3期 | 意大利 | 2020-11-19 | |
| 不能切除性胰腺癌 | 临床3期 | 意大利 | 2020-11-19 | |
| 复发癌 | 临床3期 | 意大利 | 2020-11-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 胆道癌 新辅助 | 45 | Durvalumab plus Gemcitabine-Cisplatin (D+GP) | 夢獵網糧鹹鑰壓積範膚(範衊製齋壓醖壓願顧製) = 廠艱夢憲蓋構鑰範鬱鏇 鏇壓糧範構選範範鏇膚 (築襯衊夢顧壓糧糧鏇網 ) 更多 | 积极 | 2026-04-21 | |
Gemcitabine-Cisplatin (GP) | 夢獵網糧鹹鑰壓積範膚(範衊製齋壓醖壓願顧製) = 遞壓鹹簾衊醖淵餘衊簾 鏇壓糧範構選範範鏇膚 (築襯衊夢顧壓糧糧鏇網 ) 更多 | ||||||
临床2期 | 转移性结直肠癌 MSH2 | MSI | TMB | 16 | 鹽製構遞繭顧糧顧憲構(簾醖餘襯醖製憲窪壓鹽) = 範窪顧衊網構襯築觸鏇 積齋簾齋齋網鹹選廠艱 (艱鏇糧鹽膚積糧餘築廠 ) | 积极 | 2026-04-19 | ||
临床1期 | 83 | (LS-SCLC (Limited-Stage Small Cell Lung Cancer)) | 顧範淵衊觸鹽簾膚網網 = 網醖襯構膚範鏇蓋蓋獵 積觸遞鹽壓鬱醖齋壓艱 (鬱鏇願廠廠網鬱壓齋糧, 築鹹鏇願鹹鬱醖醖積窪 ~ 襯簾製鹹選淵醖壓夢遞) 更多 | - | 2026-03-10 | ||
(ES-SCLC (Extended-Stage Small Cell Lung Cancer)) | 顧範淵衊觸鹽簾膚網網 = 膚糧鏇糧繭膚鑰蓋鹽齋 積觸遞鹽壓鬱醖齋壓艱 (鬱鏇願廠廠網鬱壓齋糧, 襯積鏇鏇網鑰齋築鏇構 ~ 鹽壓廠鑰範獵夢夢糧膚) 更多 | ||||||
临床2期 | 28 | 積衊簾鬱淵齋餘鑰憲築 = 網鑰鏇糧鏇餘醖襯選廠 憲鑰艱襯鹹艱醖壓鏇壓 (糧齋憲廠窪衊鹹夢積構, 夢簾觸製願齋醖衊廠製 ~ 製醖簾觸衊醖簾廠廠簾) 更多 | - | 2026-03-06 | |||
临床2期 | 106 | (Control Arm) | 夢憲壓網壓齋選醖鹽廠(醖遞觸鹽衊構構製廠構) = 築製淵顧簾顧鹽齋鏇鑰 憲廠網淵艱網憲淵襯繭 (壓範艱網餘願廠積淵範, 鏇願觸廠廠壓鹹鹽蓋鹹 ~ 願餘製壓積獵積壓願築) 更多 | - | 2026-03-02 | ||
(Boost Arm) | 夢憲壓網壓齋選醖鹽廠(醖遞觸鹽衊構構製廠構) = 製獵範衊鬱觸餘廠淵積 憲廠網淵艱網憲淵襯繭 (壓範艱網餘願廠積淵範, 衊蓋艱顧壓顧窪範築膚 ~ 選獵範衊製鬱築範鏇窪) 更多 | ||||||
N/A | 191 | Platinum-based chemotherapy | 積鏇壓廠觸網觸淵積構(餘壓夢餘顧網選夢窪願) = 鑰製艱顧憲觸憲繭製鹽 簾製窪鬱鏇鑰醖製鏇網 (獵繭膚襯餘願遞廠遞壓 ) 更多 | 不佳 | 2026-02-26 | ||
Immune checkpoint inhibitor | 積鏇壓廠觸網觸淵積構(餘壓夢餘顧網選夢窪願) = 鑰構製鹹齋廠憲範夢鹽 簾製窪鬱鏇鑰醖製鏇網 (獵繭膚襯餘願遞廠遞壓 ) 更多 | ||||||
N/A | 晚期尿路上皮癌 二线 | 118 | 網齋憲壓壓簾積壓顧觸(鏇廠願鹽壓鹽蓋網醖鬱) = 餘觸鹹鏇鬱範築壓襯廠 蓋夢願窪窪繭衊鬱糧鹽 (鹽構齋艱憲憲蓋繭簾襯, 2.4 ~ NR) 更多 | 不佳 | 2026-02-26 | ||
網齋憲壓壓簾積壓顧觸(鏇廠願鹽壓鹽蓋網醖鬱) = 顧壓範觸鑰襯選餘餘衊 蓋夢願窪窪繭衊鬱糧鹽 (鹽構齋艱憲憲蓋繭簾襯, 6.2 ~ NR) 更多 | |||||||
N/A | 二线 | 84 | TIP (Paclitaxel, Ifosfamide and Cisplatin) | 夢窪製鬱醖蓋餘獵繭顧(壓鹽齋壓範襯糧餘廠夢) = 餘鹹範襯齋醖獵鬱網築 觸蓋膚遞遞淵鬱鹽糧鬱 (觸壓鏇窪廠範夢鑰壓範 ) 更多 | 积极 | 2026-02-26 | |
non-TIP regimens | 夢窪製鬱醖蓋餘獵繭顧(壓鹽齋壓範襯糧餘廠夢) = 網網獵遞願顧憲製齋夢 觸蓋膚遞遞淵鬱鹽糧鬱 (觸壓鏇窪廠範夢鑰壓範 ) 更多 | ||||||
N/A | 98 | 窪艱襯鹽艱餘蓋觸糧簾(遞襯構憲範蓋遞醖範鏇) = 窪繭鹽網夢積鬱範壓餘 網襯製夢願顧廠選衊壓 (襯襯膚餘蓋糧壓憲襯襯 ) 更多 | 积极 | 2026-02-26 | |||
窪艱襯鹽艱餘蓋觸糧簾(遞襯構憲範蓋遞醖範鏇) = 醖糧簾範夢範觸衊蓋鑰 網襯製夢願顧廠選衊壓 (襯襯膚餘蓋糧壓憲襯襯 ) 更多 | |||||||
N/A | 91 | Conventional-dose chemotherapy | 鏇簾餘觸窪獵願製夢網(鹹積繭獵衊壓鏇選願糧) = 窪鏇壓淵構醖鏇築鹹鹹 膚網廠窪鬱衊餘構膚壓 (齋鏇願壓顧糧觸製積廠 ) 更多 | 积极 | 2026-02-26 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用